Zake,
Can you elaborate on #7 please.
Are you suggesting a buy/merger? if so, who do you think is a good suitor.
I for one think INSM (for the sake of us long term holders) needs to merge with someone with deep pockets, otherwise dilution will eat out positions (shares) away and we'll have to wait for splits to get them back (I can't wait that long).
By the way can't rule out a reverse split after new shelf.
If INSM does/is bought out it will be DNA or Pzifer.
Dna has the money and the back ground in the technology and Pfizer has the money, needs new pipe line and has some knowledge in the technology when they merged with Pharmacia.
Looking forward as to what you have about say on #7.
Regards,
News 
Market Data 
Discover 
